Serum levels of secreted group IIA phospholipase A 2 in benign prostatic hyperplasia and prostate cancer: A biomarker for inflammation or neoplasia?

Inflammation

Volumn 35, Issue 3, 2012, Pages 1113-1118

  Menschikowski, Mario ^a   Hagelgans, Albert ^a   Fuessel, Susanne ^a   Mareninova, Olga A ^b   Neumeister, Volker ^a   Wirth, Manfred P ^a   Siegert, Gabriele ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Benign prostatic hyperplasia; C reactive protein; Inflammation; Prostate cancer; Secreted phospholipase A 2

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; PROSTATE SPECIFIC ANTIGEN; SECRETED PHOSPHOLIPASE A2 GROUP IIA; SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; GLEASON SCORE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL;

AGED; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM GRADING; PHOSPHOLIPASES A2, SECRETORY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84863788125     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-011-9418-1     Document Type: Article

References (40)

1. Kaiser, E. 1999. Phospholipase A2: its usefulness in laboratory diagnostics. Critical Reviews in Clinical Laboratory Sciences 36: 65-163. (Pubitemid 29229706)
2. Nevalainen, T.J., M.M. Haapamäki, and J.M. Grönroos. 2000. Roles of secretory phospholipases A2 in inflammatory diseases and trauma. Biochimica et Biophysica Acta 1488: 83-90.
3. Yamaguchi, O., K. Sugimura, K. Ishizuka, K. Suzuki, K. Hasegawa, K. Ohtsuka, T. Honma, and H. Asakura. 2002. Correlation between serum phospholipase A2 IIA levels and histological activity in patients with ulcerative colitis. International Journal of Colorectal Disease 17: 311-316. (Pubitemid 36067765)
4. Nevalainen, T.J. 1993. Serum phospholipases A2 in inflammatory diseases. Clinical Chemistry 39: 2453-2459. (Pubitemid 2007974)
5. Menschikowski, M., A. Hagelgans, and G. Siegert. 2006. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins & Other Lipid Mediators 79: 1-33.
6. Triggiani, M., F. Granata, G. Giannattasio, and G. Marone. 2005. Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. The Journal of Allergy and Clinical Immunology 116: 1000-1006. (Pubitemid 41571779)
7. Scott, K.F., M. Sajinovic, J. Hein, S. Nixdorf, P. Galettis, W. Liauw, P. de Souza, Q. Dong, G.G. Graham, and P.J. Russell. 2010. Emerging roles for phospholipase A2 enzymes in cancer. Biochimie 92: 601-610.
8. Ogawa, M., S. Yamashita, K. Sakamoto, and S. Ikei. 1991. Elevation of serum group II. phospholipase A2 in patients with cancers of digestive organs. Research Communications in Chemical Pathology and Pharmacology 74: 241-244.
9. Jemal, A., F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Global cancer statistics. CA: A Cancer Journal for Clinicians 61: 69-90.
10. Kilpeläinen, T.P., T.L. Tammela, M. Roobol, J.Hugosson, S. Ciatto,V. Nelen, S. Moss, L. Määttänen, and A. Auvinen. 2011. False-positive screening results in the European randomized study of screening for prostate cancer. European Journal of Cancer 18: 2698-2705.
11. Fitzpatrick, J.M., E. Banu, and S. Oudard. 2009. Prostate-specific antigen kinetics in localized and advanced prostate cancer. British Journal of Urology International 103: 578-587.
12. Stamey, T.A., M. Caldwell, J.E. McNeal, R. Nolley, M. Hemenez, and J. Downs. 2004. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? Journal of Urology 172: 1297-1301. (Pubitemid 39249701)
13. Beer, T.M., A.S. Lalani, S. Lee, M. Mori, K.M. Eilers, J.G. Curd, W.D. Henner, C.W. Ryan, P. Venner, J.D. Ruether, and K.N. Chi. 2008. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 112: 2377-2383.
14. Heikkila, K., S. Ebrahim, and D.A. Lawlor. 2007. A systematic review of the association between circulating concentrations of C-reactive protein and cancer. Journal of Epidemiology and Community Health 61: 824-833.
15. Rintala, E.M., and T.J. Nevalainen. 1993. Synovial-type (group II) phospholipase A2 in serum of febrile patients with haematological malignancy. European Journal of Haematology 50: 11-16. (Pubitemid 23064844)
16. Nyman, K.M., W. Uhl, J. Forsström, M. Büchler, H.G. Beger, and T.J. Nevalainen. 1996. Serum phospholipase A2 in patients with multiple organ failure. Journal of Surgical Research 60: 7-14. (Pubitemid 26044291)
17. Dong, Z., Y. Liu, K.F. Scott, L. Levin, K. Gaitonde, R.B. Bracken, B. Burke, Q.J. Zhai, J. Wang, L. Oleksowicz, and S. Lu. 2010. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for Prostate Cancer. Carcinogenesis 31: 1948-1955.
18. De Nunzio, C., G. Kramer, M. Marberger, R. Montironi, W. Nelson, F. Schröder, A. Sciarra, and A. Tubaro. 2011. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. European Urology 60: 106-117.
19. Sciarra, A., G. Mariotti, S. Salciccia, A.A. Gomez, S. Monti, V. Toscano, and F. Di Silverio. 2008. Prostate growth and inflammation. The Journal of Steroid Biochemistry and Molecular Biology 108: 254-260. (Pubitemid 351179630)
20. Crowl, R.M., T.J. Stoller, R.R. Conroy, and C.R. Stoner. 1991. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. Journal of Biological Chemistry 266: 2647-2651. (Pubitemid 21909111)
21. De Marzo, A.M., E.A. Platz, S. Sutcliffe, J. Xu, H. Gronberg, C.G. Drake, Y. Nakai, W.B. Isaacs, and W.G. Nelson. 2007. Inflammation in prostate carcinogenesis. Nature Reviews. Cancer 7: 256-269. (Pubitemid 46486616)
22. Hanahan, D., and R.A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-674.
23. Grivennikov, S.I., F.R. Greten, and M. Karin. 2010. Immunity, inflammation, and cancer. Cell 140: 883-899.
24. Schenk, J.M., A.R. Kristal, M.L. Neuhouser, C.M. Tangen, E. White, D.W. Lin, M. Kratz, and I.M. Thompson. 2010. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. American Journal of Epidemiology 171: 571-582.
25. Heikkilä, K., R. Harris, G. Lowe, A. Rumley, J. Yarnell, J. Gallacher, Y. Ben-Shlomo, S. Ebrahim, and D.A. Lawlor. 2009. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a metaanalysis. Cancer Causes & Control 20: 15-26.
26. Lehrer, S., E.J. Diamond, B. Mamkine, M.J. Droller, N.N. Stone, and R.G. Stock. 2005. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU International 95: 961-962. (Pubitemid 40655687)
27. Heikkilä, K., S. Ebrahim, and D.A. Lawlor. 2008. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. European Journal of Cancer 44: 937-945.
28. Baillargeon, J., E.A. Platz, D.P. Rose, B.H. Pollock, D.P. Ankerst, S. Haffner, B. Higgins, A. Lokshin, D. Troyer, J. Hernandez, S. Lynch, R.J. Leach, and I.M. Thompson. 2006. Obesity, adipokines, and prostate cancer in a prospective populationbased study. Cancer Epidemiology, Biomarkers & Prevention 15: 1331-1335. (Pubitemid 44125290)
29. Il'yasova, D., L.H. Colbert, T.B. Harris, A.B. Newman, D.C. Bauer, S. Satterfield, and S.B. Kritchevsky. 2005. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiology, Biomarkers & Prevention 14: 2413-2418. (Pubitemid 41437845)
30. Laye, J.P., and J.H. Gill. 2003. Phospholipase A2 expression in tumours: a target for therapeutic intervention? Drug Discovery Today 8: 710-716. (Pubitemid 36970002)
31. Nagy, B., A. Szendroi, and I. Romics. 2009. Overexpression of CD24, c-myc and phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy. Pathology and Oncology Research 15: 279-283.
32. Kallajoki, M., K.A. Alanen, M. Nevalainen, and T.J. Nevalainen. 1998. Group II. phospholipase A2 in human male reproductive organs and genital tumours. Prostate 35: 263-272. (Pubitemid 28235127)
33. Graff, J.R., B.W. Konicek, J.A. Deddens, M. Chedid, B.M. Hurst, B. Colligan, B.L. Neubauer, H.W. Carter, and J.H. Carter. 2001. Expression of group IIa secretory phospholipase A2 increases with prostate tumour grade. Clinical Cancer Research 7: 3857-3861. (Pubitemid 34044601)
34. Jiang, J., B.L. Neubauer, J.R. Graff, M. Chedid, J.E. Thomas, N.W. Roehm, S. Zhang, G.J. Eckert, M.O. Koch, J.N. Eble, and L. Cheng. 2002. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. The American Journal of Pathology 160: 667-671. (Pubitemid 34160344)
35. Sved, P., K.F. Scott, D. McLeod, N.J. King, J. Singh, T. Tsatralis, B. Nikolov, J. Boulas, L. Nallan, M.H. Gelb, M. Sajinovic, G.G. Graham, P.J. Russell, and Q. Dong. 2004. Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Research 64: 6934-6940. (Pubitemid 39331002)
36. Kojima, S., D.J. Mulholland, S. Ettinger, L. Fazli, C.C. Nelson, and M.E. Gleave. 2006. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models. Prostate 66: 971-986. (Pubitemid 43853069)
37. Menschikowski, M., A. Hagelgans, E. Gussakovsky, H. Kostka, E. L. Paley, and G. Siegert. 2008. Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia 10: 279-286. (Pubitemid 351328586)
38. Mirtti, T., V.J.O. Laine, H. Hiekkanen, S. Hurme, O. Rowe, T.J. Nevalainen, M. Kallajoki, and K. Alanen. 2009. Group IIA phospholipase A2 as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality. Acta Pathologica, Microbiologica, et Immunologica Scandinavica 117: 151-161.
39. Ogawa, M., N. Sato, S. Endo, M. Kojika, Y. Yaegashi, Y. Kimura, K. Ikeda, and T. Iwaya. 2005. Group IIA-soluble phospholipase A2 levels in patients with infections after esophageal cancer surgery. Surgery Today 35: 912-918. (Pubitemid 41540058)
40. Mallat, Z., J. Benessiano, T. Simon, S. Ederhy, C. Sebella- Arguelles, A. Cohen, V. Huart, N.J. Wareham, R. Luben, K.T. Khaw, A. Tedgui, and S.M. Boekholdt. 2007. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 1177-1183. (Pubitemid 46641976)